Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Ginkgo Bioworks revenue
Ginkgo Bioworks's revenue is $227.0 million.
What is Ginkgo Bioworks's revenue?
- Ginkgo Bioworks's revenue growth from 2020 to 2024 is 196.18%.
- Ginkgo Bioworks has 200 employees, and the revenue per employee ratio is $1,135,215.
- Ginkgo Bioworks's peak quarterly revenue was $168.4M in 2022(q1).
- Ginkgo Bioworks peak revenue was $477.7M in 2022.
- Ginkgo Bioworks annual revenue for 2023 was 251.5M, -47.36% growth from 2022.
- Ginkgo Bioworks annual revenue for 2024 was 227.0M, -9.71% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Ginkgo Bioworks historical revenue
Ginkgo Bioworks's peak revenue was $477.7M in 2022. The peak quarterly revenue was $168.4M in 2022(q1).
Ginkgo Bioworks's revenue increased from $76.7m in 2020 to $227.0M currently. That's a 196.18% change in annual revenue.
Ginkgo Bioworks annual revenue
Ginkgo Bioworks annual revenue over time
| Fiscal year / year | Ginkgo Bioworks revenue |
|---|---|
| 2020 | $76.7M |
| 2021 | $313.8M |
| 2022 | $477.7M |
| 2023 | $251.5M |
| 2024 | $227.0M |
Rate Ginkgo Bioworks' financial transparency
Ginkgo Bioworks annual growth
Ginkgo Bioworks saw the greatest revenue growth in 2021, when revenue increased by 309.4%.
Ginkgo Bioworks had the lowest revenue growth in 2022, when revenue changed by 52.21%.
Ginkgo Bioworks annual growth rate over time
| Year | Ginkgo Bioworks growth |
|---|---|
| 2021 | 309%↑ |
| 2022 | 52%↑ |
| 2023 | -47%↓ |
| 2024 | -10%↓ |
Ginkgo Bioworks quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Ginkgo Bioworks quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | - | $32.1M |
| 2021 | $44.1M | $43.6M | $77.6M | $148.5M |
| 2022 | $168.4M | $144.6M | $66.4M | $98.3M |
| 2023 | $80.7M | $80.6M | $55.4M | $34.8M |
| 2024 | $37.9M | $56.2M | $89.0M | $43.8M |
Ginkgo Bioworks jobs nearby
Do you work at Ginkgo Bioworks?
Did Ginkgo Bioworks meet its revenue projections?
Ginkgo Bioworks financial information
| CEO | Jason Kelly |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 200 |
| Date Founded | 2008 |
| Headquarters | Boston, Massachusetts |
| Revenue | $227.0M |
| Net Income | -$2,104,929,000 |
| Gross Proft | $182.5M (2024) |
| Tax Rate | 0.0% |
| Total Assets | $2,539,321,000 |
| Ticker | SRNGU |
Ginkgo Bioworks jobs you might like
Ginkgo Bioworks financing
Ginkgo Bioworks received early financing of $400.0K on 2014-01-01.
| Series | Round size | Date |
|---|---|---|
| Grant | $400K | 01/2014 |
| Seed | $1M | 07/2014 |
| Series A | $9M | 03/2015 |
| Series B | $53.3M | 07/2015 |
| Series C | $100M | 06/2016 |
| Series D | $275M | 12/2017 |
| Series E | $290M | 09/2019 |
| Series F | $70M | 05/2020 |
| Post Ipo Equity | $775M | 09/2021 |
Ginkgo Bioworks investors
| Investors | Security type |
|---|---|
| MassVentures | Grant |
| CRCM | Seed |
| Farzad Nazem | Seed |
| Ken Arnold | Seed |
| Y Combinator | Seed |
| David Spector | Seed |
| 11.2 Capital | Seed |
| Todd Corenson | Seed |
| Vast Ventures | Seed |
| TSVC | Seed |
| Louis Beryl | Seed |
| Jonathan Downey | Seed |
| Azure Capital Partners | Seed |
| Arda Kutsal | Seed |
| Ken Cheng | Seed |
| DCVC | Series A |
| Vast Ventures | Series A |
| iGlobe Partners | Series A |
| Ian McNish | Series A |
| Raj Sandhu | Series A |
| Felicis Ventures | Series A |
| OS Fund | Series A |
| David Beyer | Series A |
| CRCM | Series B |
| Viking Global Investors | Series B |
| Vast Ventures | Series B |
| DCVC | Series B |
| iGlobe Partners | Series B |
| Ken Arnold | Series B |
| Y Combinator | Series B |
| 11.2 Capital | Series B |
| iD Ventures America LLC | Series B |
| Felicis Ventures | Series B |
| OS Fund | Series B |
| MassVentures | Series B |
| Cascade Investment | Series C |
| Viking Global Investors | Series C |
| Allen & Company | Series C |
| Senator Investment Group LP | Series C |
| Baillie Gifford | Series C |
| Y Combinator | Series C |
| Cascade Investment | Series D |
| Viking Global Investors | Series D |
| Y Combinator | Series D |
| General Atlantic | Series D |
| Bill Gates | Series D |
| Cascade Investment | Series E |
| Viking Global Investors | Series E |
| General Atlantic | Series E |
| T. Rowe Price | Series E |
| Viking Global Investors | Series F |
| Illumina, Inc. | Series F |
| General Atlantic | Series F |
| Cascade Investment | Post Ipo Equity |
| Viking Global Investors | Post Ipo Equity |
| ARK Investment Management | Post Ipo Equity |
| Baillie Gifford | Post Ipo Equity |
| ArrowMark Partners | Post Ipo Equity |
| Franklin Advisors | Post Ipo Equity |
| T. Rowe Price | Post Ipo Equity |
| Bain Capital Public Equity | Post Ipo Equity |
| Casdin Capital | Post Ipo Equity |
| Putnam Investments | Post Ipo Equity |
Search for jobs
Ginkgo Bioworks highest paying jobs
Zippia gives an in-depth look into the details of Ginkgo Bioworks, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ginkgo Bioworks. The employee data is based on information from people who have self-reported their past or current employments at Ginkgo Bioworks. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ginkgo Bioworks. The data presented on this page does not represent the view of Ginkgo Bioworks and its employees or that of Zippia.
Ginkgo Bioworks may also be known as or be related to Ginkgo Bioworks, Ginkgo Bioworks Inc and Ginkgo Bioworks, Inc.